- Skylight Health Group Inc. (SLHG) completes two out of 10 clinical research studies awarded and reported steady revenue growth since its launch last year
- Studies range in indication and methodology, contributing to evidence-based medicine
- The company’s total 2021 revenue was $300,000 and has already been surpassed in 2022
- In less than a year, its research practices enrolled over 1000 patients across five studies
- Skylight Health Group Inc. (SLHG) is up 27.08 per cent trading at $1.22 per share as of 1:14 p.m. ET
Skylight Health Group (SLHG) has completed two clinical research studies and has seen steady growth in revenue since its launch last year.
Skylight is a U.S.-based multi-state primary care management group.
One year ago, Skylight Health Research announced a partnership with ClinEdge to launch formal clinical research studies into its practices. Since its inception, the company has been awarded ten clinical studies and has completed two to date.
The ten studies awarded range in methodology including advancing knowledge of COVID-19, influenza patterns, cancer detection, major depressive disorder, and Lyme disease.
The company’s total revenue earned through clinical studies in 2021 was $300,000. That figure has already been surpassed in 2022. Revenue is expected to quadruple by the end of this year.
Skylight Health leveraged its growing clinical services division last year and launched Skylight Health Research.
Skylight Health research has since made several other key partnerships with research partners and contract research organizations to bring a steady supply of study opportunities to its practices.
The company’s research program has gained momentum allowing for quick start-up at multiple of its practices to bolster its research applications.
In less than a year, Skylight Health Research practices enrolled more than 1000 patients across five studies, and two of its sites were among the top performers in a competitive study that collected blood samples for the development of a cancer-detecting blood assay.
The program has grown from a single practice participating in research to five practices that will have active research initiatives by the end of Q2.
Skylight Health Group Inc. (SLHG) is up 27.08 per cent trading at $1.22 per share as of 1:14 p.m. ET.
